Sight Sciences (NASDAQ:SGHT - Free Report) had its price objective decreased by Lake Street Capital from $3.00 to $2.50 in a research note released on Thursday, Marketbeat reports. Lake Street Capital currently has a hold rating on the stock.
Several other research firms have also issued reports on SGHT. Stifel Nicolaus decreased their target price on Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday. Citigroup lowered their target price on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Morgan Stanley reduced their price target on shares of Sight Sciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Monday, November 11th. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a research report on Thursday. Finally, Piper Sandler dropped their price objective on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $3.83.
Get Our Latest Report on SGHT
Sight Sciences Trading Up 3.8 %
Sight Sciences stock traded up $0.09 during trading hours on Thursday, reaching $2.45. 679,174 shares of the company's stock traded hands, compared to its average volume of 271,457. The firm has a market capitalization of $124.35 million, a price-to-earnings ratio of -2.40 and a beta of 2.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences has a fifty-two week low of $2.17 and a fifty-two week high of $8.45. The firm's 50 day moving average is $2.90 and its 200-day moving average is $4.38.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The business had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.98 million. During the same quarter in the prior year, the company earned ($0.22) earnings per share. On average, analysts predict that Sight Sciences will post -0.99 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO Paul Badawi sold 12,236 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total value of $44,049.60. Following the completion of the transaction, the chief executive officer now directly owns 5,713,197 shares of the company's stock, valued at approximately $20,567,509.20. This represents a 0.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 63,014 shares of company stock worth $197,295 over the last ninety days. Company insiders own 28.90% of the company's stock.
Institutional Trading of Sight Sciences
A number of institutional investors have recently modified their holdings of SGHT. GSA Capital Partners LLP bought a new position in shares of Sight Sciences during the third quarter worth about $136,000. Millrace Asset Group Inc. acquired a new position in Sight Sciences during the 3rd quarter worth approximately $874,000. Jacobs Levy Equity Management Inc. boosted its position in Sight Sciences by 46.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company's stock worth $1,310,000 after acquiring an additional 65,767 shares during the last quarter. State Street Corp grew its stake in shares of Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company's stock worth $4,075,000 after acquiring an additional 95,843 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of Sight Sciences by 317.4% in the third quarter. Barclays PLC now owns 50,300 shares of the company's stock valued at $317,000 after purchasing an additional 38,248 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Read More
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
